摘要
目的:探讨阿格列汀联合二甲双胍对初诊2型糖尿病(type 2 diabetes mellitus,T2DM)患者胰岛β细胞功能及炎症状态的影响。方法:选取2015年3月至2018年8月深圳市盐田区人民医院收治的初诊T2DM患者124例,以随机数字表法分为观察组和对照组,每组62例。采用相同的治疗原则,对照组患者给予二甲双胍,观察组患者给予二甲双胍联合阿格列汀治疗,两组患者均持续治疗6个月。观察两组患者临床疗效,空腹血糖(FPG)、餐后2h血糖(2hPG)、胰岛β细胞指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)、血白细胞介素18(IL-18)、超敏C反应蛋白(hs-CRP)、糖化血红蛋白(HbA1c)水平及不良反应发生情况。结果:观察组患者的总有效率为93.55%(58/62),明显高于对照组的80.65%(50/62),差异有统计学意义(P<0.05)。治疗后,两组患者FPG、2hPG、HOMA-IR及HbA1c水平较治疗前明显降低,HOMA-β水平明显升高;且观察组患者FPG、2hPG、HOMA-IR及HbA1c水平明显低于对照组,HOMA-β水平明显高于对照组,差异均有统计学意义(P<0.05)。治疗后,两组患者血IL-18、hs-CRP水平较治疗前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。两组患者无明显不良反应发生。结论:阿格列汀联合二甲双胍治疗初诊T2DM患者的疗效显著,可改善胰岛β细胞功能,减轻炎症状态,且安全性高。
OBJECTIVE:To probe into the effects of alogliptin combined with metformin on pancreatic β cell function and inflammatory state in patients with newly diagnosed type 2 diabetes (T2DM).METHODS:124 patients with T2DM admitted into Shenzhen Yantian District People’s Hospital from Mar.2015 to Aug.2018 were selected and divided into observation group and control group via random number table,with 62 cases in each group.Under the same therapeutic principle,the control group was treated with metformin,while the observation group was given alogliptin combined with metformin,both groups were treated for 6 months.The clinical efficacy,fasting plasma glucose (FPG),2 h postprandial plasma glucose (2 hPG),indices of pancreatic β cell (HOMA-β),insulin resistance indices (HOMA-IR),blood interleukin-18 (IL-18),expression of high sensitivity C-reactive protein (hs-CRP), glycosylated hemoglobin(HbA1c) and incidences of adverse drug reactions of the two groups were observed.RESULTS:The total effective rate of observation group was 93.55%(58/62),which was significantly higher than that of the control group (80.65%,50/62),with statistically significant difference ( P <0.05).After treatment,the FPG,2 hPG,HOMA-IR and HbA 1c levels of both groups had been significantly decreased,while the HOMA-β level was significantly increased;the FPG,2 hPG,HOMA-IR and HbA 1c levels of observation group were significantly lower than those of the control group,the HOMA-β level of observation group was significantly higher than the control group,with statistically significant differences ( P <0.05).After treatment,the IL-18 and hs-CRP levels of both groups had been significantly decreased,and those of the observation group were significantly lower than the control group,with statistically significant differences ( P <0.05).No obvious adverse drug reactions occurred in both group.CONCLUSIONS:The efficacy of alogliptin combined with metformin in treatment of patients with newly diagnosed T2DM is remarkable,which can improve pancreatic β cell function and relief inflammatory state,with high safety.
作者
郑志刚
于敏
唐平
陈巧红
ZHENG Zhigang;YU Min;TANG Ping;CHEN Qiaohong(Dept.of Internal Medicine,Shenzhen Yantian District People’s Hospital,Guangdong Shenzhen 518083,China)
出处
《中国医院用药评价与分析》
2019年第9期1089-1091,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
深圳市科技研发资金(No.JCYJ20150403111252444)
关键词
阿格列汀
二甲双胍
初诊2型糖尿病
胰岛Β细胞功能
炎症状态
Alogliptin
Metformin
Newly diagnosed type 2 diabetes
Pancreatic β cell function
Inflammatory state
